Sunshine Heart Inc.
Despite a long road ahead, Sunshine Heart is worth a serious look
Sunshine Heart seeks $25.5M in equity funding round | Wall Street Beat
Eden Prairie, Minn., and Sydney-based medical device company Sunshine Heart (ASX:SHC) is looking to raise funds in a $25.5 million equity funding round, according to document filed with the SEC earlier this month.
Hospitals: Cap-ex market still constrained | Wall Street Beat
Mako Surgical (NSDQ:MAKO) Rio robotic surgery system needs to move from ‘nice to have’ to ‘need to have’ if it’s going to gain traction with hospitals.
That’s because the capital expenditure market is still under pressure from the weak economy, according to Leerink Swann analyst Richard Newitter, citing the un-named hospital CFO.
Sunshine Heart rises on FDA approval for next-gen C-Pulse blood pump
Sunshine Heart (ASX:SHC) won conditional approval from the FDA for the next generation of its flagship C-Pulse heart assist system, an outside-the-bloodstream left ventricular assist device that helps circulate blood and reduce the pumping burden on a patient’s heart.
Sunshine Heart soars on C-Pulse CE Mark | Wall Street Beat
Sunshine Heart (ASX:SHC) is shining on Wall Street today after announcing European regulatory approval for its C-Pulse heart assist system, with SHC shares closing up nearly 14% on the news.
MassDevice.com +3 | The top 3 med-tech stories for April 30, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Sunshine Heart’s David Rosa: “Patients don’t like being tethered to a device”
Click here to listen to the podcast
"In the U.S., for Class III heart failure there are about 1.5 million patients," Sunshine Heart CEO David Rosa told MassDevice.com in an exclusive podcast interview. "That’s about 7 times the Class IV market, which is traditionally where LVADs participate."
HeartWare lands FDA OK for extended trial ahead of PMA review | Regulatory Roundup
TCT 2011: Medtronic, Boston Scientific, Abbott continue the Stent Wars
Stents: FDA approves TriVascular’s Ovation stent graft system | Regulatory Roundup
TriVascular Inc. landed U.S. humanitarian device exemption approval for its Ovation abdominal stent graft system used to repair abdominal aneurysms.
The 20 mm Ovation system was approved by the FDA on Nov. 1 for use in patients with small iliac or femoral artery access of less than 7 millimeters.